RxDoctor Payments Data

Julie Cahill, MD

Family Medicine · Sedalia, MONPI 1104883925

Payments from drug & device makers

$778in general payments, 2019–2025

Across 72 payments — averaging $10.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$332
  • Pfizer$207
  • Sanofi$180
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$44
  • GSK$15

What the payments were for

  • Speaking & faculty fees$18023%
  • Food & beverage$53969%
  • Education$598%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)42$332
Pfizer24$207
Sanofi2$180
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$44
GSK1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$778 in reported general payments places this provider in the 60th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$127,002
Medicare patients
415
Services billed
2,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide125$115,280
MounjaroTirzepatide59$68,904
EliquisApixaban92$59,407
JardianceEmpagliflozin53$48,174
JanuviaSitagliptin Phosphate43$37,825
XareltoRivaroxaban38$35,997
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$20,084
TrulicityDulaglutide18$18,735
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$15,956
LinzessLinaclotide27$14,110
PremarinEstrogens, Conjugated17$12,395
ShingrixVaricella-Zoster Ge/As01b/Pf46$9,419
SymbicortBudesonide/Formoterol Fumarate29$8,205
SavellaMilnacipran Hcl11$7,868
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$7,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$207$71,802109 claims
AbbVieLinzess, Savella$332$21,97738 claims
GSKShingrix, Arexvy$15$14,74867 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Sedalia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →